Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 472 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Rate Reduction Clear all
Terminated Phase 2 Interventional Results available

Efficacy Study of Recombinant Protein (Ecallantide) to Reduce Blood Loss During Primary Coronary Bypass Grafting or Valve Repair/Replacement

NCT00448864
View directory record Official record
Conditions
Blood Loss, Surgical
Interventions
Ecallantide, Placebo
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
15
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 18, 2026, 5:02 AM EDT
Withdrawn No phase listed Observational

Bronchiectasis: Evaluation of an Educational Intervention

NCT01315626
View directory record Official record
Conditions
Bronchiectasis
Interventions
Primary Care Educational event
Other
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Shelbyville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2015 · Synced Oct 18, 2026, 5:02 AM EDT
Recruiting Phase 2 Interventional

Limiting AAA With Metformin (LIMIT) Trial

NCT04500756
View directory record Official record
Conditions
Abdominal Aortic Aneurysm
Interventions
Metformin, Placebo
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 95 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 18, 2026, 5:02 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

The Association Between Fluid Administration, Oxytocin Administration, and Fetal Heart Rate Changes

NCT00787176
View directory record Official record
Conditions
Pregnancy, Labor Pain
Interventions
Group A Intravenous bolus of 1000 ml lactated ringers solution, Group B Intravenous bolus bolus 1000 ml lactated ringers solution oxytocin decrease to 1/2 current rate, Group C 125 mL/hr of lactated ringers, Group D 125 mL/hr lactated ringers oxytocin decreased to 1/2 current rate
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
251 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Pilot Study on the Submental Area

NCT01859091
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq System
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 18, 2026, 5:02 AM EDT
Terminated Not applicable Interventional Results available

Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

NCT00871845
View directory record Official record
Conditions
Obesity, Insulin Resistance, Metabolic Syndrome, Hepatitis C
Interventions
Dietary and Lifestyle modification educational sessions
Behavioral
Lead sponsor
Hossam Kandil
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Phase 1 Interventional

Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants

NCT00606437
View directory record Official record
Conditions
Lymphoma, Myeloma, Leukemia, Myelodysplasia, Solid Tumors, Hodgkin's Disease, Myelofibrosis
Interventions
Total Body Irradiation with Fludarabine in UCB Transplants
Procedure
Lead sponsor
Duke University
Other
Eligibility
14 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Impact of Weight Loss on Physical Function

NCT02079051
View directory record Official record
Conditions
Obesity
Interventions
Moderate intensity weight loss, High intensity medical weight loss
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 18, 2026, 5:02 AM EDT
Recruiting Phase 2 Interventional

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

NCT03587272
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Alemtuzumab, low dose total body irradiation, Sirolimus
Drug
Lead sponsor
Robert Nickel
Other
Eligibility
2 Years to 25 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Not applicable Interventional Results available

Omnipod® 5 Automated Insulin Delivery System in Patients With Type 2 Diabetes

NCT04617795
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Omnipod 5 Automated Insulin Delivery System
Device
Lead sponsor
Insulet Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
4
States / cities
Los Angeles, California • Atlanta, Georgia • Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 18, 2025 · Synced Oct 18, 2026, 5:02 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Comparing Clinical Performance of Novice Trainee Endoscopists Using Conventional Air Insufflation Versus Warm Water Infusion Colonoscopy

NCT01482546
View directory record Official record
Conditions
Colonoscopy Education
Interventions
Not listed
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2017 · Synced Oct 18, 2026, 5:02 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Biobehavioral Mechanisms of Activity and Loss of Control Eating in Children

NCT07823153
View directory record Official record
Conditions
Binge Eating Behaviour, Eating Disorders, Physical Activity, Functional Magnetic Resonance Imaging (fMRI), Ecological Momentary Assessment, Loss of Control Eating
Interventions
Go/No-go task, Visual food task, Emotion regulation task
Behavioral
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
10 Years to 12 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2030
U.S. locations
3
States / cities
Los Angeles, California • Richardson, Texas • Fairfax, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Phase 1Phase 2 Interventional

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT04815720
View directory record Official record
Conditions
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)
Interventions
pepinemab + pembrolizumab
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Springdale, Arkansas • Fresno, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2025 · Synced Oct 18, 2026, 5:02 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Effects of a Short-term Aerobic Interval Exercise Program on Cardiac Fat and Function in Women With Obesity: A Pilot Study

NCT04802005
View directory record Official record
Conditions
Obesity
Interventions
Aerobic Interval Training
Other
Lead sponsor
Southern Illinois University Edwardsville
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Edwardsville, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

NCT05601882
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 64 Years
Enrollment
920 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
58
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • North Little Rock, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2025 · Synced Oct 18, 2026, 5:02 AM EDT
Withdrawn Not applicable Interventional

Heart Rate Variability (HRV) to Evaluate Surgical Risk on Patients on Beta Blockers

NCT01330654
View directory record Official record
Conditions
Cardiac Event Risk
Interventions
metoprolol
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Telehealth Based Intervention to Improve Functional Capacity in Survivors of Childhood Cancer With Significantly Limited Exercise Tolerance

NCT04714840
View directory record Official record
Conditions
Childhood Cancer, Mobility Limitation
Interventions
Exercise testing results, Individually tailored exercise program (INT), Generalized exercise recommendations (AC)
Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years to 39 Years
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of Vilaprisan in Renal Impairment

NCT03411980
View directory record Official record
Conditions
Uterine Fibroids, Endometriosis
Interventions
Vilaprisan (BAY1002670)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 79 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 18, 2026, 5:02 AM EDT
Withdrawn Not applicable Interventional

Efficacy of Remodulin in Adults With Congenital Heart Disease (ACHD) and Pulmonary Hypertension

NCT01980979
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Remodulin
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Los Angeles, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2017 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Feasibility Study of a Belt Applicator

NCT01767142
View directory record Official record
Conditions
Body Fat Disorder
Interventions
The Zeltiq System with Modified Belt Applicator
Device
Lead sponsor
Zeltiq Aesthetics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Marina del Rey, California • Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Optimizing a Digital AEP Risk Intervention With Native Women and Communities

NCT06324929
View directory record Official record
Conditions
Alcohol Exposed Pregnancy, Unplanned Pregnancy, Alcohol Use, Unspecified, Contraception Use, Sexual Behavior
Interventions
CARRII Native Rapid Pilot Testing
Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 44 Years · Female only
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Phase 2 Interventional

Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC)

NCT01915602
View directory record Official record
Conditions
Carcinoma, Hepatocellular
Interventions
Refametinib (BAY86-9766), Sorafenib (BAY43-9006)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 18, 2026, 5:02 AM EDT
Completed Not applicable Interventional

Effects of Creatine Supplementation in Breast Cancer Survivors

NCT04207359
View directory record Official record
Conditions
Breast Cancer, Chemotherapy Effect, Muscle Weakness, Muscle Loss, Exercise
Interventions
Creatine
Dietary Supplement
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 18, 2026, 5:02 AM EDT